Related Experiment Video
Updated: Nov 22, 2025
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived
Anusha Thadi1, William F Morano1, Marian Khalili1
1Division of Surgical Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, U.S.A.
Background/Aim:
We have tested whether the anticancer peptide, PNC-27, that kills cancer cells but not normal cells by binding to cancer cell membrane HDM-2 forming pores, kills CD44+ colon cancer stem cells.
Materials And Methods:
Flow cytometry determined the CD44 and HDM-2 expression on six-colon cancer cell lines and one normal cell line (CCD-18Co). MTT, LDH release, annexin V binding and caspase 3 assays were used to assess PNC-27-induced cell death. Bioluminescence imaging measured PNC-27 effects on in vivo tumor growth.
Results:
High percentages of cells in all six tumor lines expressed CD44. PNC-27 co-localized with membrane HDM-2 only in the cancer cells and caused total cell death (tumor cell necrosis, high LDH release, negative annexin V and caspase 3). In vivo, PNC-27 caused necrosis of tumor nodules but not of normal tissue.
Conclusion:
PNC-27 selectively kills colon cancer stem cells by binding of this peptide to membrane H/MDM-2.
Insights
The anticancer peptide PNC-27 effectively eliminates colon cancer stem cells by targeting the HDM-2 protein on their membranes. This selective action results in cancer cell death without harming normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Colon cancer stem cells (CD44+) are crucial for tumor growth and recurrence.
- The peptide PNC-27 demonstrates selective cancer cell killing via HDM-2 membrane binding and pore formation.
Purpose of the Study:
- To evaluate the efficacy of PNC-27 against CD44-positive colon cancer stem cells.
- To determine the mechanism of PNC-27's action on these specific cancer cells.
Main Methods:
- Flow cytometry to assess CD44 and HDM-2 expression in colon cancer cell lines and normal cells.
- Cell death assays (MTT, LDH release, annexin V, caspase 3) to measure PNC-27's impact.
- Bioluminescence imaging for in vivo tumor growth assessment.
Main Results:
- All six colon cancer cell lines exhibited high CD44 expression.
- PNC-27 localized to HDM-2 on cancer cell membranes, inducing necrosis and cell death.
- In vivo studies confirmed PNC-27's tumor-specific necrosis without affecting normal tissues.
Conclusions:
- PNC-27 selectively targets and eradicates colon cancer stem cells.
- The peptide's mechanism involves binding to membrane HDM-2, leading to cancer cell death.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...